Wall Street analysts expect Forty Seven Inc (NASDAQ:FTSV) to post earnings per share (EPS) of ($0.56) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Forty Seven’s earnings. The company is scheduled to announce its next quarterly earnings results on Monday, November 12th.
According to Zacks, analysts expect that Forty Seven will report full-year earnings of ($2.96) per share for the current fiscal year, with EPS estimates ranging from ($3.51) to ($2.41). For the next fiscal year, analysts anticipate that the firm will report earnings of ($2.73) per share, with EPS estimates ranging from ($3.05) to ($2.41). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Forty Seven.
Forty Seven (NASDAQ:FTSV) last released its earnings results on Monday, August 13th. The company reported ($2.52) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($1.84).
In other Forty Seven news, major shareholder Ravi Mhatre purchased 166,858 shares of the stock in a transaction dated Thursday, August 23rd. The shares were purchased at an average cost of $15.08 per share, with a total value of $2,516,218.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Christopher J. Schaepe purchased 66,542 shares of the stock in a transaction dated Thursday, August 16th. The shares were acquired at an average cost of $15.03 per share, for a total transaction of $1,000,126.26. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 300,900 shares of company stock worth $4,540,995.
Several large investors have recently made changes to their positions in FTSV. Point72 Hong Kong Ltd bought a new position in Forty Seven in the second quarter valued at about $120,000. Waddell & Reed Financial Inc. bought a new position in Forty Seven in the second quarter valued at about $160,000. Janus Henderson Group PLC bought a new position in Forty Seven in the second quarter valued at about $160,000. DAFNA Capital Management LLC bought a new position in Forty Seven in the second quarter valued at about $160,000. Finally, TD Asset Management Inc. bought a new position in Forty Seven in the second quarter valued at about $215,000. 41.05% of the stock is currently owned by hedge funds and other institutional investors.
Forty Seven stock opened at $14.58 on Tuesday. Forty Seven has a 12 month low of $12.16 and a 12 month high of $16.86.
Forty Seven Company Profile
Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; and FSI-189, an antibody that binds to SIRPa for the treatment of solid tumors.
Recommended Story: Market Capitalization
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Forty Seven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forty Seven and related companies with MarketBeat.com's FREE daily email newsletter.